Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaglenastat and Chemoradiation in Advanced Cervical Cancer
NCT05521997Phase 2Not yet recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2026
- Primary completion
- Mar 2033
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of telaglenastat in Cervical Cancer (CC), sponsored by Washington University School of Medicine. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
telaglenastat
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05521997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521997.